Literature DB >> 31300595

Randomized comparison between perineural dexamethasone and dexmedetomidine for ultrasound-guided infraclavicular block.

Julián Aliste1, Sebastián Layera2, Daniela Bravo2, Diego Fernández2, Álvaro Jara2, Armando García3, Roderick J Finlayson4, De Q Tran5.   

Abstract

BACKGROUND: This randomized trial compared perineural dexamethasone (5 mg) and dexmedetomidine (100 µg) for ultrasound-guided infraclavicular brachial plexus block. We hypothesized that both adjuvants would result in similar durations of motor block and therefore designed the study as an equivalence trial (equivalence margin=3.0 hours).
METHODS: One hundred and twenty patients undergoing upper limb surgery with ultrasound-guided infraclavicular block (using 35 mL of lidocaine 1%-bupivacaine 0.25% with epinephrine 5 µg/mL) were randomly allocated to receive perineural dexamethasone (5 mg) or dexmedetomidine (100 µg). Patients and operators were blinded to the nature of the perineural adjuvant. After the performance of the block, a blinded observer assessed the success rate (defined as a minimal sensorimotor composite score of 14 out of 16 points at 30 min) as well as the incidence of surgical anesthesia (defined as the ability to complete surgery without local infiltration, supplemental blocks, intravenous opioids, or general anesthesia). Heart rate and blood pressure were recorded before the block as well as during the first 2 hours after its performance. Furthermore, the level of sedation (using the Ramsay Sedation Scale) was recorded in the postanesthesia care unit. Postoperatively, the blinded observer contacted patients with successful blocks to inquire about the duration of motor block, sensory block, and postoperative analgesia.
RESULTS: No intergroup differences were observed in terms of success rate and surgical anesthesia. Compared with dexmedetomidine, dexamethasone provided longer durations of motor block (17.4 (4.0) vs 14.3 (3.0) hours; p<0.001; 95% CI 1.7 to 4.5), sensory block (19.0 (4.0) vs 15.0 (3.2) hours; p<0.001; 95% CI 2.6 to 5.4), and analgesia (22.2 (3.6) vs 16.9 (3.9) hours; p<0.001; 95% CI 3.7 to 6.9). Dexmedetomidine resulted in lower heart rate and blood pressure after the performance of the block, as well as an increased level of sedation postoperatively.
CONCLUSION: Compared with dexmedetomidine (100 µg), dexamethasone (5 mg) results in longer sensorimotor block and analgesic durations, as well as a decreased level of patient sedation. Further studies are required to compare dexamethasone and dexmedetomidine using different doses, local anesthetic agents, and approaches to the brachial plexus. TRIAL REGISTRATION NUMBER: NCT03610893. © American Society of Regional Anesthesia & Pain Medicine 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute pain; brachial plexus; upper extremity

Year:  2019        PMID: 31300595     DOI: 10.1136/rapm-2019-100680

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  3 in total

Review 1.  A Comprehensive Review and Update of the Use of Dexmedetomidine for Regional Blocks.

Authors:  Ivan Urits; Celina Guadalupe Virgen; Hamed Alattar; Jai Won Jung; Amnon A Berger; Hisham Kassem; Islam Mohammad Shehata; Amir Elhassan; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2020-10-15

Review 2.  Comparison of postoperative analgesic effects in response to either dexamethasone or dexmedetomidine as local anesthetic adjuvants: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Zhen-Guo Song; Shen-Yue Pang; Gui-Yue Wang; Zhao Zhang
Journal:  J Anesth       Date:  2021-01-30       Impact factor: 2.078

3.  Efficacy of Dexamethasone versus Dexmedetomidine Combined with Local Anaesthetics in Brachial Plexus Block: A Meta-Analysis and Systematic Review.

Authors:  Ming Li; Pinghu Zhang; Duangao Wei
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-01       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.